What's being tested:
OTHER: Diagnostic test: EBV antibody tests
Eligibility: Inclusion Criteria: * Subject residents in Zhongshan or Wuzhou City; * Subject has no medical record of prevalent cancer; * Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\'s follow-up procedures. Exclusion…
What's being tested:
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
DRUG: Cyclophosphamide
DRUG: Cyclosporine
Eligibility: Inclusion Criteria: * Acute leukemia (AL) that includes acute myeloid leukemia (AML) / acute lymphoblastic leukemia (ALL) / mixed phenotype leukemia (MPAL) in complete morphological remission (CR) with or without detectable minimal residual disease (MRD); complete morphological…
What's being tested:
DRUG: Apatinib+ SHR-1210（Camrelizumab）
DRUG: Apatinib+ SHR-1316（Adebrelimab）
DRUG: SHR-1316（Adebrelimab）+SHR-A2009
Eligibility: Inclusion Criteria: 1. Aged 18-75 years, males or females; 2. Histologically or cytologically confirmed as ESCC, locally advanced and unresectable, with local recurrence (local lymph node metastases) or distant metastases; 3. First-line patients who progressed or were intolerant…
What's being tested:
DRUG: Intramuscular quadratus lumborum block
DRUG: Lateral quadratus lumborum block
DRUG: General anesthesia
Eligibility: Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status II-III. * Body mass index (BMI): (20- 40) kg/m2. * Type of surgery: midline incision for unilateral open nephrectomy. Exclusion Criteria: * Patient refusal.…
Eligibility: Inclusion Criteria: * Patients with biopsy-proven cervical cancer FIGO stage IA-IIA undergoing surgery; * Women aged \>18 years old; * Signed Informed Consent. Exclusion Criteria: * Concurrent malignancies at other sites; * Previous history of neoplasm; * Refusal to sign writt…
Eligibility: * INCLUSION CRITERIA: * Eligible participants must: * Have a dermatologic condition, as determined by the PI or AIs, OR --be at risk for developing a dermatologic condition, as determined by the PI or AIs, OR * be a family member of a person with a dermatologic condition OR…
Eligibility: Inclusion Criteria: * Inclusion in TICIMEL clinical trial (NCT03293784), * Inclusion in MELANFα trial (NCT03348891) Exclusion Criteria: * NA
What's being tested:
DRUG: Anlotinib hydrochloride
Eligibility: Inclusion Criteria: 1. Patients voluntarily participate in this study, sign informed consent, and demonstrate good compliance. 2. Patients with histologically or pathologically confirmed EGFR wild-type and EGFR mutant non-small cell lung cancer resistant to treatment. 3. The num…
What's being tested:
DRUG: Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the "Zyest Technology Tarawat Zendig" institute in Iran. The dosage of ASX is determined based on the s
DRUG: Placebo
Eligibility: Inclusion Criteria: 1. Age 18 - 45 years 2. Clinical diagnosis of polycystic ovary syndrome 3. Have a body mass index of 25-35 kg/m 2 4. Absence of pregnancy and breastfeeding 5. No intake of medicine 6. Not willing to get pregnant during the study 7. No presence of chronic infl…
What's being tested:
RADIATION: stereotactic body raiotherapy
Eligibility: Inclusion Criteria: 1. Aged ≥18 years; 2. Confirmed diagnosis of soft tissue sarcomas; 3. Highly malignant soft tissue sarcomas; 4. Not received surgery, chemotherapy or other antitumor therapy; 5. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1; 6. Signed in…
What's being tested:
DRUG: mFOLFIRINOX plus IMRT
Eligibility: Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. * Age ≥ 18 years and ≤ 80 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Histologically or cytologically confirmed advanced pancreas adenoca…
Eligibility: Inclusion Criteria: 1. Adults ≥ 18 years old 2. Patients (irrespective of sex and gender) with pathologically documented breast cancer that: * is unresectable or metastatic * has confirmed HER2+, HER2-low or HER2-ultralow tumor status by local pathology * was previousl…
What's being tested:
DRUG: HRS-4642 Injection
Eligibility: Inclusion Criteria: Participants must meet all of the following criteria to be eligible for this study: 1. Age ≥18 years and ≤75 years, regardless of gender. 2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. 3. Radiologically confirmed locally advan…
What's being tested:
DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Venetoclax Oral Product
Eligibility: Inclusion Criteria: In cohort A, subject must meet the following inclusion criteria: 1. Subject must be primary refractory or in progression within 24 months from initiation of first line treatment (POD24 defined as time between D1C1 of the first treatment line and ICF signatur…
What's being tested:
OTHER: Non-interventional Study
Eligibility: Inclusion Criteria: * Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamo…
What's being tested:
DRUG: Patritumab deruxtecan
DRUG: Olaparib
Eligibility: Inclusion Criteria: 1. Patients must have received prior treatment with T-DXd and presented disease progression while on T-DXd treatment or within 2 months from T-DXd interruption/discontinuation for any reason, without requiring to be the last line of treatment. Patients who ha…
What's being tested:
DIAGNOSTIC_TEST: Blood test
Eligibility: Inclusion Criteria: \- Histologically or cytologically verified NSCLC stage II-IV (OMD) according to UICC TNM8 edition considered operable in curative intent after neoadjuvant systemic therapy containing immune checkpoint inhibition by local multidisciplinary tumor board (MDT) d…
What's being tested:
BEHAVIORAL: RACS app
Eligibility: Inclusion Criteria: * Inclusion Criteria: * Aged 60 years and older; * Ethnic/racial background consistent with NIH policy * Male or female * Fluent in Spanish. Exclusion Criteria: * Confounding conditions that could impact ability to participate in the study (e.g., cognitive…
What's being tested:
OTHER: Prehabilitation
Eligibility: Inclusion Criteria: * 65 years or older * cT1 kidney tumor, scheduled for either partial or radical nephrectomy. * Clinical Frailty Scale 3-6 Exclusion Criteria: * It is determined by an attending physician, or at a multi-disciplinary team-conference, that a 2-4 week postponem…
What's being tested:
OTHER: No intervention
Eligibility: Inclusion Criteria: 1. Pathological type: high-grade serous adenocarcinoma of the ovary 2. Pathological slices stored within 5 years 3. FIGO stage II or above 4. Complete clinical and follow-up data Exclusion Criteria: 1. Slice quality control failure 2. Incomplete follow-up d…
Showing 1–20 of 18,820 results
Trial data sourced from
ClinicalTrials.gov (U.S. National Library of Medicine). Data may be delayed. Verify enrollment status directly with the research team.